A retrospective analysis on the utility and complications of upper arm ports in 433 cases at a single institute

Int J Clin Oncol. 2016 Jun;21(3):474-82. doi: 10.1007/s10147-015-0917-1. Epub 2015 Oct 27.

Abstract

Background: We have employed upper arm central venous ports (UACVPs) since 2006 for long-term intravenous chemotherapy (CTx) or fluid supplementation. We evaluated the long-term availability of CVPs implanted in the upper arm to determine whether UACVPs could be one of the treatment options besides chest CVPs in terms of CVP-related complications.

Methods: We reviewed the medical records of all patients who underwent subcutaneous implantation of UACVPs at Kyoto University Hospital from 1 April, 2006 to 30 June, 2009. We assessed the indwelling duration of the UACVPs and the incidences of early and late UACVP-related complications.

Results: A total of 433 patients underwent subcutaneous implantation of UACVPs during this time period. The cumulative follow-up period was 251,538 catheter days, and the median duration of UACVP indwelling was 439.0 days (1-2, 24). There was no UACVP-related mortality throughout the study period. A total of 83 UACVP-related complications occurred (19.2 %), including 43 cases of infection (9.9 %, 0.17/1000 catheter days), ten cases of catheter-related thrombosis (2.3 %, 0.040/1000 catheter days), ten cases of occlusion (2.3 %, 0.040/1000 catheter days), nine cases of catheter dislocation (2.0 %, 0.036/1000 catheter days), five cases of port leakage (1.2 %, 0.019/1000 catheter days), four cases of skin dehiscence (0.9 %, 0.015/1000 catheter days) and two cases of port chamber twist (0.5 %, 0.008/1000 catheter days). The removal-free one-year port availability was estimated at 87.8 %.

Conclusions: UACVPs were of long-term utility, with complication rates comparable to those of chest CVPs previously reported.

Keywords: CVP-related complications; Long-term availability; Upper arm central venous ports.

MeSH terms

  • Administration, Intravenous
  • Aged
  • Antineoplastic Agents / administration & dosage*
  • Arm*
  • Catheter Obstruction
  • Catheterization, Central Venous / adverse effects*
  • Catheters, Indwelling / adverse effects*
  • Central Venous Catheters / adverse effects*
  • Device Removal
  • Female
  • Fluid Therapy
  • Humans
  • Male
  • Middle Aged
  • Neoplasms / drug therapy*
  • Prosthesis Failure
  • Retrospective Studies
  • Thrombosis / etiology
  • Time Factors

Substances

  • Antineoplastic Agents